Rivoceranib not checked

Hengrui

FollowEvery change as it happens, and a Monday email
Stage
in China
Next date
Phase 2 trial completes
Trials
3 active
19 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Subjects receive Rivoceranib (Apatinib) orally, Dosage form: tablet”In the company’s words, NCT04639180 on ClinicalTrials.gov
Tested for
Gastric Cancer, Hepatocellular Carcinoma (HCC), Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk
Main trialPhase 3
“This is a study for participants with advanced gastric or gastroesophageal junction adenocarcinoma who have had tumor progression after first-line platinum-contained therapy. The primary study hypotheses are that camrelizumab (SHR-1210) combined with apatinib prolongs overall survival (OS) for participants with tumors that show positive programmed cell death ligand 1 (PD-L1) expression.”In the company’s words, NCT04342910 on ClinicalTrials.gov
Other names
Apatinib · Apatinib Mesylate

Other drugs for Gastric Cancer

All 208 drugs for Gastric Cancer

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials19

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 1 Apr 2026 Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Phase 3Active, not recruiting 31 Jul 2026 A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
Phase 2Not yet recruiting Jul 2027 A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma
Phase 3Completed 15 Dec 2017 Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)
Phase 3Terminated 29 Dec 2021 A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
Phase 3Completed 8 Feb 2022 A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
Phase 3Terminated 14 Apr 2023 A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.
Phase 3Completed 7 Jun 2023 A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy
Phase 2Completed Jul 2013 A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma
Phase 2Completed 25 Nov 2020 A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer
Phase 2Completed 31 Mar 2021 A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC
Phase 2Completed 4 Aug 2021 SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy
Phase 2Completed 22 Apr 2022 A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)
Phase 2Terminated 29 Jun 2023 Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer
Phase 1Completed 6 Jul 2020 A Food Effect Study of Apatinib Mesylate in Healthy Subjects
Phase 1Unknown Feb 2021 Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients
Phase 1Completed 3 Apr 2021 A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects
Phase 1Completed 20 May 2021 A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects
Phase 1Completed 22 Aug 2021 A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Rivoceranib

Following is part of Solo: you see every change to Rivoceranib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in